[Biphosphonates and osteogenesis imperfecta in children]

Area of Science:

• Pediatric Orthopaedics
• Pharmacology
• Bone Metabolism

Background:

• Osteogenesis imperfecta (OI) is a rare genetic disorder characterized by brittle bones.
• Severe and moderate forms of OI significantly impact children's quality of life and mobility.
• Traditional treatments like physiotherapy and surgery have limitations in managing severe OI.

Purpose of the Study:

• To review the established role of biphosphonate therapy in managing pediatric osteogenesis imperfecta.
• To detail the indications, administration protocols, and safety profile of biphosphonate treatment in children.
• To discuss the long-term skeletal retention and efficacy of biphosphonates in pediatric OI patients.

Main Methods:

• Systematic review of biphosphonate therapy in pediatric OI management.
• Analysis of clinical data on efficacy, safety, and administration of biphosphonates.
• Evaluation of studies reporting on the duration and long-term skeletal persistence of biphosphonates.

Main Results:

• Biphosphonate therapy has been a key advancement in OI management for over 10 years.
• Established protocols exist for indications, administration routes, and treatment duration.
• Safety data indicates a generally favorable profile, but long-term skeletal persistence requires further investigation.

Conclusions:

• Biphosphonate therapy is a cornerstone in the multidisciplinary management of pediatric osteogenesis imperfecta.
• Understanding administration and safety is crucial for optimal patient outcomes.
• Further research is needed to clarify the long-term skeletal fate and sustained benefits of biphosphonates in children.